Curious to see your top suppliers emissions?
Book a demo for a pilot project
Sarepta Therapeutics
Pharmaceutical Preparation ManufacturingUnited StatesNASDAQ: SRPT
Last verified 6 days agosarepta.com
Sarepta Therapeutics, Inc., a leading player in the pharmaceutical preparation manufacturing industry, is headquartered in the United States. Founded in 1980, the company has made significant strides in developing innovative therapies for rare genetic diseases, particularly Duchenne muscular dystrophy (DMD). With a strong focus on gene therapy and precision medicine, Sarepta's core products, including its pioneering exon-skipping treatments, set it apart in the competitive landscape.
The company has achieved notable milestones, including the first FDA-approved gene therapy for DMD, solidifying its position as a market leader. Operating primarily in the US, Sarepta Therapeutics continues to expand its research and development efforts, aiming to transform the lives of patients with debilitating conditions through cutting-edge biopharmaceutical solutions.
25
DitchCarbon score
-15 vs industry average
Sarepta Therapeutics’s score of 25 is lower than 38% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at Sarepta Therapeutics?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Very Low
Pharmaceutical Preparation Manufacturing is among the least carbon-intensive industries
Industry performance
0.243
02025
The Pharmaceutical Preparation Manufacturing industry has increased its overall emissions by 132% since 0
Emissions trajectory 2020 – 2026
2020202120222023202420252026
Reported emissions
Scope 1
•••kg CO₂e
Scope 2
•••kg CO₂e
Scope 3
•••kg CO₂e
Total reported
•••kg CO₂e
Scope 3 accounts for ••• of total emissions.
Sarepta Therapeutics's reported carbon emissions
Sarepta Therapeutics, a pharmaceutical preparation manufacturing company based in the US, reported total emissions of approximately 8.43 million kg CO2e in 2023. This figure encompasses Scope 1 and Scope 2 emissions, amounting to about 3.43 million kg CO2e for Scope 1 and approximately 5.00 million kg CO2e for Scope 2.
In 2022, Sarepta Therapeutics’s total emissions were approximately 7.49 million kg CO2e. This included about 2.70 million kg CO2e from Scope 1 and approximately 4.79 million kg CO2e from Scope 2.
The company has not publicly disclosed Scope 3 emissions data for these years, with "purchased goods and services" identified as a missing data point. Sarepta Therapeutics has not set any specific science-based reduction targets or joined climate initiatives like the Science Based Targets initiative (SBTi) or the Climate Pledge, as per the provided information. Their climate commitments and reduction initiatives are not detailed in the available data.
Unlock detailed emission data
Access structured emission data, company specific factors and auditable source documents
Sarepta Therapeutics’s Climate Goals (2030 & 2050)
No climate goals have been disclosed for Sarepta Therapeutics yet.
Scope 3 top emissions categories
No scope 3 category breakdown has been disclosed yet.
Emissions comparison with industry peers
View similar organisationsCompanyCountryIndustryLast updatedScoreDetails
Sarepta Therapeutics6 days ago
25
Usage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn more